| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary targets of 653-47 hydrochloride include CREB (cAMP-response element binding protein) and Wnt signaling pathways. It is a potentiator that significantly enhances the CREB inhibitory activity of 666-15. It is also a very weak CREB inhibitor with an IC50 of 26.3 μM. The compound is a valuable tool for probing Wnt pathway biology and developing targeted therapies against Wnt-driven pathologies.
|
|---|---|
| ln Vitro |
In synergy with 666-15, 653-47 (5-10 μM) suppresses CREB-mediated gene transcription[1].
In vitro, 653-47 hydrochloride (5-10 μM) synergistically inhibits CREB-mediated gene transcription with 666-15. It is a potentiator that significantly enhances the CREB inhibitory activity of 666-15. The compound is also a very weak CREB inhibitor with an IC50 of 26.3 μM. It suppresses CREB-mediated gene transcription at 5-10 μM. |
| ln Vivo |
In vivo activity of 653-47 hydrochloride has not been extensively characterized. It has been investigated for its therapeutic potential in cancers and fibrotic diseases where aberrant Wnt signaling plays a critical role. However, detailed in vivo pharmacokinetic and pharmacodynamic studies are limited. The compound is primarily studied for its in vitro activities.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 653-47 hydrochloride are not typically performed, as the compound is a potentiator of CREB inhibition rather than a direct enzyme inhibitor. Quality control assays involve HPLC to verify purity (≥98%) and identity. The compound is tested for solubility and stability under standard storage conditions. It is soluble in DMSO at 250 mg/mL (613.81 mM).
|
| Cell Assay |
In vitro cellular assays for 653-47 hydrochloride involve testing its effects on CREB-mediated gene transcription. Cells are treated with 653-47 hydrochloride (5-10 μM) in combination with 666-15. CREB-mediated gene transcription is measured by reporter assays or qRT-PCR. The compound demonstrates synergistic inhibition of CREB-mediated gene transcription with 666-15.
|
| Animal Protocol |
In vivo animal studies for 653-47 hydrochloride are limited, as the compound is primarily studied in vitro. For efficacy testing, animal models of cancer or fibrotic diseases could be used. Animals would be treated with 653-47 hydrochloride via oral or intraperitoneal administration at various doses, and relevant biomarkers would be assessed. However, detailed in vivo protocols are not well established in the available literature.
|
| ADME/Pharmacokinetics |
653-47 hydrochloride has a molecular formula of C20H20Cl2N2O3 and a molecular weight of 407.29. It appears as a solid powder with a purity of ≥98%. It is soluble in DMSO at 250 mg/mL (613.81 mM). The compound should be stored in dry, dark conditions at -20°C for up to 1 year. Stock solutions can be stored at 0-4°C for 1 month. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 653-47 hydrochloride has not been extensively characterized. As a research compound, standard toxicity studies would include assessment of acute oral toxicity, repeated-dose toxicity, and genotoxicity in animal models. The compound is intended for research use only and is not approved for clinical use.
|
| References | |
| Additional Infomation |
653-47 hydrochloride (CAS 1224567-46-7) is a potentiator that significantly enhances the CREB inhibitory activity of 666-15 and is also a very weak CREB inhibitor with an IC50 of 26.3 μM. It has a molecular formula of C20H20Cl2N2O3 and a molecular weight of 407.29. The compound has been investigated for its therapeutic potential in cancers and fibrotic diseases where aberrant Wnt signaling plays a critical role. It is intended for research use only and is not approved for clinical use.
|
| Molecular Formula |
C20H20CL2N2O3
|
|---|---|
| Molecular Weight |
407.2904
|
| Exact Mass |
406.085
|
| CAS # |
1224567-46-7
|
| Related CAS # |
653-47;1224678-75-4
|
| PubChem CID |
46187341
|
| Appearance |
Pale purple to purple solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
464
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C([H])=C([H])C(=C(C=1[H])O[H])N([H])C(C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C([H])=C1OC([H])([H])C([H])([H])C([H])([H])N([H])[H])=O.Cl[H]
|
| InChi Key |
HESNWSHDEFHION-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H19ClN2O3.ClH/c21-15-6-7-17(18(24)12-15)23-20(25)16-10-13-4-1-2-5-14(13)11-19(16)26-9-3-8-22;/h1-2,4-7,10-12,24H,3,8-9,22H2,(H,23,25);1H
|
| Chemical Name |
3-(3-aminopropoxy)-N-(4-chloro-2-hydroxyphenyl)naphthalene-2-carboxamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (613.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4553 mL | 12.2763 mL | 24.5525 mL | |
| 5 mM | 0.4911 mL | 2.4553 mL | 4.9105 mL | |
| 10 mM | 0.2455 mL | 1.2276 mL | 2.4553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
